Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients

Samih H Nasr; Surendra Dasari; John C. Lieske; Linda M. Benson; Patrick M. Vanderboom; Carrie J. Holtz-Heppelmann; Callen D. Giesen; Melissa R. Snyder; Stephen B. Erickson; Fernando C. Fervenza; Nelson Leung; Paul J. Kurtin; Mariam P. Alexander

doi:10.1016/j.kint.2019.01.024

Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients

Samih H Nasr, Surendra Dasari, John C. Lieske, Linda M. Benson, Patrick M. Vanderboom, Carrie J. Holtz-Heppelmann, Callen D. Giesen, Melissa R. Snyder, Stephen B. Erickson, Fernando C. Fervenza, Nelson Leung, Paul J. Kurtin, Mariam P. Alexander

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Fibrillary glomerulonephritis (FGN) is a rare glomerular disease. Kidney biopsy is required to establish the diagnosis. Recent studies have identified abundant glomerular deposition of DNAJB9 as a unique histological marker of FGN. We developed an immunoprecipitation-based multiple reaction monitoring method to measure serum levels of DNAJB9. We detected a 4-fold higher abundance of serum DNAJB9 in FGN patients when compared to controls, including patients with other glomerular diseases. Serum DNAJB9 levels were also negatively associated with estimated glomerular filtration rate in patients with FGN. Serum DNAJB9 levels accurately predicted FGN with moderate sensitivity (67%) and with high specificity (98%) and positive and negative predictive value (89% and 95%, respectively). A receiver operating curve analysis demonstrated an AUC of 0.958. These results suggest that serum levels of DNAJB9 could be a valuable marker to predict FGN, with the potential to complement kidney biopsy for the diagnosis of FGN.

Original language	English (US)
Pages (from-to)	1269-1272
Number of pages	4
Journal	Kidney international
Volume	95
Issue number	5
DOIs	https://doi.org/10.1016/j.kint.2019.01.024
State	Published - May 2019

Keywords

DNAJB9
biomarker
fibrillary glomerulonephritis
immuno-MRM
proteomics
serum

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.kint.2019.01.024

Cite this

Nasr, S. H., Dasari, S., Lieske, J. C., Benson, L. M., Vanderboom, P. M., Holtz-Heppelmann, C. J., Giesen, C. D., Snyder, M. R., Erickson, S. B., Fervenza, F. C., Leung, N., Kurtin, P. J., & Alexander, M. P. (2019). Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients. Kidney international, 95(5), 1269-1272. https://doi.org/10.1016/j.kint.2019.01.024

@article{a333a3c8b14f43bba21621ecb36db543,

title = "Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients",

abstract = "Fibrillary glomerulonephritis (FGN) is a rare glomerular disease. Kidney biopsy is required to establish the diagnosis. Recent studies have identified abundant glomerular deposition of DNAJB9 as a unique histological marker of FGN. We developed an immunoprecipitation-based multiple reaction monitoring method to measure serum levels of DNAJB9. We detected a 4-fold higher abundance of serum DNAJB9 in FGN patients when compared to controls, including patients with other glomerular diseases. Serum DNAJB9 levels were also negatively associated with estimated glomerular filtration rate in patients with FGN. Serum DNAJB9 levels accurately predicted FGN with moderate sensitivity (67%) and with high specificity (98%) and positive and negative predictive value (89% and 95%, respectively). A receiver operating curve analysis demonstrated an AUC of 0.958. These results suggest that serum levels of DNAJB9 could be a valuable marker to predict FGN, with the potential to complement kidney biopsy for the diagnosis of FGN.",

keywords = "DNAJB9, biomarker, fibrillary glomerulonephritis, immuno-MRM, proteomics, serum",

author = "Nasr, {Samih H} and Surendra Dasari and Lieske, {John C.} and Benson, {Linda M.} and Vanderboom, {Patrick M.} and Holtz-Heppelmann, {Carrie J.} and Giesen, {Callen D.} and Snyder, {Melissa R.} and Erickson, {Stephen B.} and Fervenza, {Fernando C.} and Nelson Leung and Kurtin, {Paul J.} and Alexander, {Mariam P.}",

note = "Publisher Copyright: {\textcopyright} 2019 International Society of Nephrology",

year = "2019",

month = may,

doi = "10.1016/j.kint.2019.01.024",

language = "English (US)",

volume = "95",

pages = "1269--1272",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients

AU - Nasr, Samih H

AU - Dasari, Surendra

AU - Lieske, John C.

AU - Benson, Linda M.

AU - Vanderboom, Patrick M.

AU - Holtz-Heppelmann, Carrie J.

AU - Giesen, Callen D.

AU - Snyder, Melissa R.

AU - Erickson, Stephen B.

AU - Fervenza, Fernando C.

AU - Leung, Nelson

AU - Kurtin, Paul J.

AU - Alexander, Mariam P.

PY - 2019/5

Y1 - 2019/5

N2 - Fibrillary glomerulonephritis (FGN) is a rare glomerular disease. Kidney biopsy is required to establish the diagnosis. Recent studies have identified abundant glomerular deposition of DNAJB9 as a unique histological marker of FGN. We developed an immunoprecipitation-based multiple reaction monitoring method to measure serum levels of DNAJB9. We detected a 4-fold higher abundance of serum DNAJB9 in FGN patients when compared to controls, including patients with other glomerular diseases. Serum DNAJB9 levels were also negatively associated with estimated glomerular filtration rate in patients with FGN. Serum DNAJB9 levels accurately predicted FGN with moderate sensitivity (67%) and with high specificity (98%) and positive and negative predictive value (89% and 95%, respectively). A receiver operating curve analysis demonstrated an AUC of 0.958. These results suggest that serum levels of DNAJB9 could be a valuable marker to predict FGN, with the potential to complement kidney biopsy for the diagnosis of FGN.

AB - Fibrillary glomerulonephritis (FGN) is a rare glomerular disease. Kidney biopsy is required to establish the diagnosis. Recent studies have identified abundant glomerular deposition of DNAJB9 as a unique histological marker of FGN. We developed an immunoprecipitation-based multiple reaction monitoring method to measure serum levels of DNAJB9. We detected a 4-fold higher abundance of serum DNAJB9 in FGN patients when compared to controls, including patients with other glomerular diseases. Serum DNAJB9 levels were also negatively associated with estimated glomerular filtration rate in patients with FGN. Serum DNAJB9 levels accurately predicted FGN with moderate sensitivity (67%) and with high specificity (98%) and positive and negative predictive value (89% and 95%, respectively). A receiver operating curve analysis demonstrated an AUC of 0.958. These results suggest that serum levels of DNAJB9 could be a valuable marker to predict FGN, with the potential to complement kidney biopsy for the diagnosis of FGN.

KW - DNAJB9

KW - biomarker

KW - fibrillary glomerulonephritis

KW - immuno-MRM

KW - proteomics

KW - serum

UR - http://www.scopus.com/inward/record.url?scp=85064076426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064076426&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2019.01.024

DO - 10.1016/j.kint.2019.01.024

M3 - Article

C2 - 31010480

AN - SCOPUS:85064076426

SN - 0085-2538

VL - 95

SP - 1269

EP - 1272

JO - Kidney international

JF - Kidney international

IS - 5

ER -

Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this